以嶺藥業(002603.SZ)子公司擬斥50.34億元投建現代中藥產業化項目
格隆匯11月15日丨以嶺藥業(002603.SZ)公佈，2019年11月15日，公司第六屆董事會第二十七次會議審議通過了《關於全資子公司投資建設現代中藥產業化項目的議案》。公司擬以衡水以嶺為項目實施主體，投資建設“衡水以嶺藥業有限公司現代中藥產業化項目”，該項目生產產品主要包括中藥配方顆粒、中藥片劑及保健品。項目計劃投資總額人民幣約50.34億元，項目資金來源為衡水以嶺自籌資金。該項目計劃已取得河北省企業投資項目備案證明。
公司擬通過衡水以嶺項目建設，建立符合要求的生產基地，擴大中藥配方顆粒、中藥片劑、保健品的生產規模和生產能力，推動公司中藥板塊和大健康板塊發展，進一步增強公司的市場競爭力。
項目名稱：衡水以嶺藥業有限公司現代中藥產業化項目；項目具體實施內容：項目總佔地面積約110.74萬平方米(合1661.16畝)，總建築面積約121.66萬平方米，主要建設內容包括飲片加工車間、提取車間、製劑車間、保健品車間、榨油車間及鍋爐房、倉儲等生產及輔助設施。項目建設達產後將實現年產中藥飲片4200噸、配方顆粒4500噸、中藥提取物4500噸、中藥片劑30億片及中藥保健品軟膠囊10億粒、保健食品500噸、保健飲料1000噸生產能力，為未來公司發展和市場擴張打下良好的基礎。
項目總投資估算為50.34億元。其中建設投資約48.32萬元，鋪底流動資金2.03億元。項目建設期3年，建設投資計劃在建設期內投入，投入比例為第一年40%，第二年40%，第三年20%。
項目建成達產後，預計可實現年銷售收入約57.70億元，淨利潤約26.90億元，投資回收期約4.96年(上述經濟效益預測並不代表公司對未來盈利的保證，能否實現取決於市場狀況的變化、經營團隊管理水平等多種因素的影響，存在着一定的不確定性，請投資者注意風險)。
項目建設是出於公司未來發展的戰略性考慮，符合公司做大做強主營業務的發展戰略，既有利於進一步完善公司中藥、健康產業生產基地的戰略佈局，擴大中藥片劑、中藥飲片、保健品產能，又可為公司未來發展中藥配方顆粒、中藥提取物業務做好產能儲備，從而達到優化公司產品結構的目的，對於提升公司核心競爭力具有重要意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
